BioCryst Pharmaceuticals (BO1) Stock Overview
A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
BO1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BioCryst Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.11 |
| 52 Week High | US$10.19 |
| 52 Week Low | US$5.18 |
| Beta | 0.57 |
| 1 Month Change | -2.15% |
| 3 Month Change | -2.44% |
| 1 Year Change | -25.34% |
| 3 Year Change | -4.46% |
| 5 Year Change | -44.45% |
| Change since IPO | 55.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| BO1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.5% | -3.1% | -2.9% |
| 1Y | -25.3% | -8.0% | -0.8% |
Return vs Industry: BO1 underperformed the German Biotechs industry which returned -8% over the past year.
Return vs Market: BO1 underperformed the German Market which returned -0.8% over the past year.
Price Volatility
| BO1 volatility | |
|---|---|
| BO1 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: BO1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BO1's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 435 | Charlie Gayer | www.biocryst.com |
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial.
BioCryst Pharmaceuticals, Inc. Fundamentals Summary
| BO1 fundamental statistics | |
|---|---|
| Market cap | €1.83b |
| Earnings (TTM) | -€396.75m |
| Revenue (TTM) | €767.30m |
Is BO1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BO1 income statement (TTM) | |
|---|---|
| Revenue | US$885.72m |
| Cost of Revenue | US$207.02m |
| Gross Profit | US$678.70m |
| Other Expenses | US$1.14b |
| Earnings | -US$457.98m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.80 |
| Gross Margin | 76.63% |
| Net Profit Margin | -51.71% |
| Debt/Equity Ratio | -152.2% |
How did BO1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 23:22 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioCryst Pharmaceuticals, Inc. is covered by 27 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Steven Seedhouse | Cantor Fitzgerald & Co. |